Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?

But the Galaxies Lung-201 trial features notable omissions, plus toxicity.

Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.

The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.

The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.

Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.